Christian Schade - May 18, 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: Chairman & CEO, Director
Signature: /s/ Scott M. Coiante, attorney-in-fact
Stock symbol: APRE
Transactions as of: May 18, 2022
Transactions value $: $24,124
Form type: 4
Date filed: 5/19/2022, 04:30 PM
Previous filing: May 17, 2022
Next filing: Jun 7, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Purchase	$24.1K	+37.5K	+14.7%	$0.64^*	293K	May 18, 2022	Direct	F1
holding	APRE	Common Stock						1K	May 18, 2022	By adult child	F2
holding	APRE	Common Stock						1K	May 18, 2022	By adult child	F2
holding	APRE	Common Stock						1K	May 18, 2022	By adult child	F2
holding	APRE	Common Stock						1K	May 18, 2022	By adult child	F2
holding	APRE	Common Stock						1K	May 18, 2022	By adult child	F2
holding	APRE	Common Stock						1K	May 18, 2022	By adult child	F2
holding	APRE	Common Stock						5K	May 18, 2022	By spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6245 to $0.6675, inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2	The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.

Content

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6245 to $0.6675, inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.